APA (7th ed.) Citation

Huang, H., Wang, T., Li, W., Wu, Z., Wang, X., Xing, J., . . . Zhang, K. (2025). Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): Study protocol for an open-label prospective phase II umbrella clinical trial. BMC Cancer, 25(1), 1. https://doi.org/10.1186/s12885-025-13826-5

Chicago Style (17th ed.) Citation

Huang, Haichao, Tao Wang, Wei Li, Zhun Wu, Xuegang Wang, Jinchun Xing, Bin Chen, and Kaiyan Zhang. "Safety and Efficacy of Genomic Biomarker-guided Neoadjuvant Therapy for Locally Advanced and Oligometastatic Prostate Cancer (SEGNO): Study Protocol for an Open-label Prospective Phase II Umbrella Clinical Trial." BMC Cancer 25, no. 1 (2025): 1. https://doi.org/10.1186/s12885-025-13826-5.

MLA (9th ed.) Citation

Huang, Haichao, et al. "Safety and Efficacy of Genomic Biomarker-guided Neoadjuvant Therapy for Locally Advanced and Oligometastatic Prostate Cancer (SEGNO): Study Protocol for an Open-label Prospective Phase II Umbrella Clinical Trial." BMC Cancer, vol. 25, no. 1, 2025, p. 1, https://doi.org/10.1186/s12885-025-13826-5.